The new MHRA accredited unit has been actively running trials in its new surroundings since March 25th with excellent on-going patient feedback.

Our new facility is an early phase specialist unit, it is the fourth unit Richmond Pharmacology has opened and we believe it is our best to date. Richmond Pharmacology completely removed the existing facilities in the building and designed all the floors from scratch creating a better patient experience in the process. The new site has previously been used for conducting early Phase trials for more than 30 years.

It is in an ideal location embedded in the King’s College University and teaching hospital campus."The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market."

Richmond Pharmacology CEO, Dr Jorg Taubel.Our integrated, MHRA licensed clinical trials pharmacy is staffed by an experienced and dedicated team, supervised by two expert QPs providing quality and flexible service, GMP advice and regulatory support to our clients.Located in centre of London, within close walking distance to key transport links, museums, historic attractions and all that London has to offer, Richmond believes the location will offer unrivalled access to patent recruitment enabling Richmond to maintain its position as Market Leaders in Combined Adaptive Early Phase Trials.

Latest news

Five Years Since a World-First CRISPR Breakthrough at Richmond Pharmacology

December 8, 2025
In November 2020, Richmond Pharmacology made medical history when a patient received the first-ever systemically delivered CRISPR therapy, using lipid nanoparticles to edit genes directly inside the human body.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event